CD4 and neoplasm: Recently, Renaudet and coworkers showed a four-component HER-GLP vaccine construct (one CD4+ T-cell epitope, one OVA CD8+ T-cell epitope, one carbohydrate B-cell epitope and a built-in palmitic acid adjuvant) inhibited the tumor growth in HER-GLP immunized mice [21].